Bullous pemphigoid: From bench to bedside

Drugs

Volumn 65, Issue 7, 2005, Pages 905-926

  Walsh, Scott R A ^a   Hogg, David ^a   Mydlarski, P Régine ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIODARONE; AMPICILLIN; ANTIBIOTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; BULLOUS PEMPHIGOID ANTIGEN 1; BULLOUS PEMPHIGOID ANTIGEN 180; BUMETANIDE; CAPTOPRIL; CEFALEXIN; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; ENALAPRIL; ERYTHROMYCIN; FLUOROURACIL; FLUOXETINE; FUROSEMIDE; IBUPROFEN; IMMUNOGLOBULIN; INFLUENZA VACCINE; INTERLEUKIN 2; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OMEPRAZOLE; PENICILLAMINE; PENICILLIN G; PHENACETIN; PREDNISOLONE; PREDNISONE; PSORALEN; RISPERIDONE; SPIRONOLACTONE; SULFAPYRIDINE; SULFONAMIDE; TETANUS TOXOID; TETRACYCLINE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ALOPECIA; ANTIBODY DETECTION; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BASEMENT MEMBRANE; BLISTER; BONE MARROW SUPPRESSION; BONE NECROSIS; CANDIDIASIS; CATARACT; CHRONIC DISEASE; DIABETES MELLITUS; DRUG POTENCY; ELDERLY CARE; ERYTHRODERMA; FATIGUE; FLUSHING; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMIDESMOSOME; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; HYPERTENSION; IMMUNOELECTRON MICROSCOPY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER TOXICITY; LUNG FIBROSIS; LUPUS VULGARIS; METHEMOGLOBINEMIA; MOLECULAR BIOLOGY; NAUSEA; OSTEOPOROSIS; PEMPHIGOID; PERIPHERAL NEUROPATHY; PHOTOTOXICITY; PNEUMONIA; PRURITUS; PSYCHOSIS; PUVA; RASH; REVIEW; SEPSIS; STOMATITIS; TERATOGENICITY; VERTIGO; VIRUS INFECTION;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; GLUCOCORTICOIDS; HUMANS; PEMPHIGOID, BULLOUS; TETRACYCLINE;

EID: 18644370861     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565070-00002     Document Type: Review

References (294)

1. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Arch Dermatol 1995; 131: 48-52
2. Zillikens D, Wever S, Roth A, et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of Central Germany. Arch Dermatol 1995; 131: 957-8
3. Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol 1999; 41: 266-8
4. Korman NJ. Bullous pemphigoid. J Am Acad Dermatol 1987; 16: 907-24
5. Lever WF. Pemphigus and pemphigoid. J Am Acad Dermatol 1979; 1: 2-31
6. Yenning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 1992; 26: 585-9
7. Korman NJ. Bullous pemphigoid: the latest in diagnosis, prognosis and therapy. Arch Dermatol 1998; 134: 1137-41
8. Savin JA. Some factors affecting prognosis in pemphigus vulgaris and pemphigoid. Br J Dermatol 1981; 104: 415-20
9. Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134: 465-9
10. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid. Arch Dermatol 2002; 138: 903-8
11. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Arch Dermatol 1977; 113: 1043-6
12. Taylor G, Yenning VA, Wojnarowska FT, et al. Bullous pemphigoid and autoimmunity. J Am Acad Dermatol 1993; 29: 181-4
13. Delgado JC, Turbay D, Yunis EJ, et al. A common major histocompatibility complex class II allele HLA-DQB*0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci USA 1996; 93: 8569-71
14. Banfield CC, Wojnarowska F, Allen J, et al. The association of HLA-DQ7 with bullous pemphigoid is restricted to men. Br J Dermatol 1998; 138: 1085-90
15. Budinger L, Borradori L, Yee C, et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 1998; 102: 2082-9
16. Schaller J, Feleke W, Haustein UF, et al. HLA in bullous pemphigoid: the probable role of HLA-B7 as a marker for poor responders to immunosuppressive therapy. Int J Dermatol 1991; 30: 36-8
17. Giannini JM, Callen JP, Gruber GG. Bullous pemphigoid and rheumatoid arthritis. J Am Acad Dermatol 1981; 4: 695-7
18. Clayton CA, Burnham TK. Systemic lupus erythematosus and coexisting bullous pemphigoid: immunofluorescent investigations. J Am Acad Dermatol 1982; 7: 236-45
19. Stoll DM, King LE. Association of bullous pemphigoid with systemic lupus erythematosus. Arch Dermatol 1984; 120: 362-6
20. Huang CY, Chen TC. Bullous pemphigoid associated with systemic lupus erythematosus: the discrimination of antibasement membrane zone antibody. Int J Dermatol 1997; 36: 40-2
21. Goihman-Yahr M. Familial occurrence of coexistence of bullous pemphigoid and Sjogren's syndrome. Int J Dermatol 1998; 37: 475-6
22. Masouye I, Schmied E, Didierjean L, et al. Bullous pemphigoid and multiple sclerosis: more than a coincidence? J Am Acad Dermatol 1989; 21: 63-8
23. James WD. Bullous pemphigoid, myasthenia gravis, and thymoma. Arch Dermatol 1984; 120 (3): 397
24. Hamilton DV, McKenzie AW. Bullous pemphigoid and primary biliary cirrhosis. Br J Dermatol 1978; 99: 447-50
25. Singhal PC, Scharschmidt LA. Membranous nephropathy associated with primary biliary cirrhosis and bullous pemphigoid. Ann Allergy 1985; 55: 484-5
26. Simon CA, Winkelmann RK. Bullous pemphigoid and glomerulonephritis. J Am Acad Dermatol 1986; 14: 456-63
27. Ross EA, Ahmed AR. Bullous pemphigoid-associated nephropathy: report of two cases and review of the literature. Am J Kidney Dis 1989; 19 (3): 225-9
28. Bryning K, Leslie J. Factor V inhibitor and bullous pemphigoid. BMJ 1977; 1: 677-8
29. Earth JH, Kelly SE, Wojnarowska F, et al. Pemphigoid and ulcerative colitis. J Am Acad Dermatol 1988; 19: 303-8
30. Harrison PV, Blewitt RW, Allen J, et al. Bullous pemphigoid and ulcerative colitis: a report of two cases and description of immunoblot findings. Br J Dermatol 1996; 134: 599-600
31. Nowicki MJ, Bishop PR, Parker PH. Bullous pemphigoid complicating Crohn's disease in a child. Clin Pediatr 2002; 41: 59-62
32. Chorzelski TP, Maciejowski E, Jablonska S, et al. Coexistence of pemphigus and bullous pemphigoid. Arch Dermatol 1974; 109: 849-53
33. Heine KG, Kumar A, Jordan RE. Pemphigus-like antibodies in bullous pemphigoid. Arch Dermatol 1977; 113: 1693-5
34. Leibovici V, Ron N, Goldenhersh M, et al. Coexistence of pemphigus and bullous pemphigoid. Int J Dermatol 1989; 28: 259-60
35. Ninomiya J, Nakabayashi A, Sei Y, et al. Bullous pemphigoid complicated with pemphigus vulgaris? Dermatology 1994; 189 Suppl. 1: 117-9
36. Sami N, Ahmed AR. Dual diagnosis of pemphigus and pemphigoid. Dermatology 2001; 202: 293-301
37. Sami N, Bhol KC, Beutner EH, et al. Diagnostic features of pemphigus vulgaris in patients with bullous pemphigoid. Dermatology 2002; 204: 108-17
38. Harrington CI, Sneddon IB. Coexistence of bullous pemphigoid and pemphigus foliaceus. Br J Dermatol 1979; 100: 441-5
39. Rantanen T, Niemi K. A further case of coexisting bullous pemphigoid and pemphigus foliaceus. Br J Dermatol 1979; 101: 611-2
40. Korman NJ, Stanley JR, Woodley DT. Coexistence of pemphigus foliaceus and bullous pemphigoid. Arch Dermatol 1991; 127: 387-90
41. Bhat L, Sams HH, King LE. Bullous pemphigoid associated with Castleman's disease. Arch Dermatol 2001; 137: 965-6
42. Bachmeyer C, Seoud J, Carlotti A, et al. Bullous pemphigoid associated with acute myocarditis. Dermatology 2002; 204: 161-2
43. Ahmed AR, Kaplan RP, Hardy D, et al. Bullous pemphigoid and ulcerative colitis. Int J Dermatol 1982; 21: 594-8
44. Vaccaro M, D'Amico D, Borgia F, et al. Bullous pemphigoid following use of sulphasalazine for ulcerative colitis: drug-induced eruption or true association? Dermatology 2001; 203: 194-5
45. Barnadas MA, Gelpi C, Rocamora V, et al. Bullous pemphigoid associated with acute glomerulonephritis. Br J Dermatol 1998; 138: 867-71
46. Chosidow O, Doppler V, Bensimon G, et al. Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding bullous pemphigoid? Arch Dermatol 2000; 136: 521-4
47. Grattan CEH. Evidence of an association between bullous pemphigoid and psoriasis. Br J Dermatol 1985; 113: 281-3
48. Stone SP, Schroeter AL. Pullous pemphigoid and associated malignant neoplasms. Arch Dermatol 1975; 111: 991-4
49. Ahmed AR, Amerian ML. Correlation of serum anti-basement membrane zone antibody and malignancy in bullous pemphigoid. Dermatologica 1985; 171: 82-5
50. Hadi SM, Barnetson RC, Gawkrodger DJ, et al. Clinical, histological and immunologica studies in 50 patients with bullous pemphigoid. Dermatologia 1988; 176: 6-17
51. Lindelof B, Islam N, Eklund G, et al. Pemphigoid and cancer. Arch Dermatol 1990; 126: 66-8
52. Chang YT, Liu HN, Wong CK. Bullous pemphigoid: a report of 86 cases from Taiwan. Clin Exp Dermatol 1996; 21: 20-2
53. Hodge L, Marsden RA, Black MM, et al. Bullous pemphigoid: the frequency of mucosal involvement and concurrent malignancy related to indirect mmunofluorescence findings. Br J Dermatol 1981; 105: 65-9
54. Binet O, Brunetiere RA, Rabary G, et al. Immunologic studies of bullous pemphigoid associated with adenocarcinoma of the colon. N Engl J Med 1983; 308 (8): 460-1
55. Stanley JR, Hawley-Nelson P, Yuspa SH, et al. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified sqiamous epithelia. Cell 1981; 24: 897-903
56. Sawamura D, Li K, Chu ML, et al. Human bullous pemphigoid antigen (BPAG1). J Biol Chem 1991; 266 (27): 17784-90
57. Tanaka T, Parry DAD, Klaus-Kovtun V, et al. Comparison of molecularly cloned bullous pemphigoid antigen to desmoplakin I confirms that they define a new family of cell adhesion junction plaque proteins. J Biol Chem 1991; 266 (19): 12555-9
58. Borradori L, Sonnenberg A. Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol 1999; 112: 411-8
59. Mutasim DF, Takahashi Y, Labib RS, et al. A pool of bullous pemphigoid antigen(s) is intracellular and associated with the basal cell cytoskeleton-hemidesmosome complex. J Invest Dermatol 1985; 84: 47-53
60. Ishiko A, Shimizu H, Kikuchi A, et al. Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemisdesmosome in normal human and swine skin. J Clin Invest 1993; 91: 1608-15
61. Yang Y, Dowling J, Yu QC, et al. An essential cytoskeletal linker protein connecting actin microfilaments to intermediate filaments. Cell 1996; 86: 555-65
62. Borradori L, Chavanas S, Schaapveld RQJ, et al. Role of the bullous pemphigoid 180 (BP180) in the assembly of hemidesmosomes and cell adhesion: re-expression of BP180 in generalized atrophic benign epidermolysis bullosa keratinocytes. Exp Cell Res 1998; 239: 463-76
63. Schaapveld RQJ, Bonadori L, Geerts D, et al. Hemidesmosomes formation is initiated by the β4 integrin subunit, requires complet formation with HD1/plectin and involves a direct interaction between β4 and the bullous pemphigoid antigen 180. J Cell Biol 1998; 142: 271-84
64. Okumura M, Yamakawa H, Ohara O, et al. Novel alternative splicings of BPAG1 (bullous pemphigoid antigen 1) including the domain structure closely related to MACF (microtubule actin cross-linking factor). J Biol Chem 2002; 277 (8): 6682-7
65. Mueller S, Klaus-Kovtun V, Stanley JR. A 230-kD basic protein is the major bullous pemphigoid antigen. J Invest Dermatol 1989; 92: 33-8
66. Hirako Y, Usukura J, Nishizawa N, et al. Demonstration of the molecular shape of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer formation. J Biol Chem 1996; 271 (23): 13739-45
67. Aho S, Uitto J. Direct interaction between the intracellular domains of bullous pemphigoid antigen 2 (BP180) and (34 integrin, hemidesmosomal components of basal keratinocytes. Biochem Biophys Res Commun 1998; 243: 694-8
68. Hopkinson SB, Findlay K, DeHart GW, et al. Interaction of BP180 (type XVII collagen) and α6 integrin is necessary for stabilization of hemidesmosome structure. J Invest Dermatol 1998; 111: 1015-22
69. Masunaga T, Shimizu H, Yee C, et al. The extracellular domain of BPAG2 localizes to anchoring filaments and its carboxyl terminus extends to the lamina densa of normal human epidermal basement membrane. J Invest Dermatol 1997; 109: 200-6
70. Giudice GJ, Squiquera HL, Elias PM, et al. Identification of two collagen domains within the bullous pemphigoid autoantigen, BP180. J Clin Invest 1991; 87: 734-8
71. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992; 99: 243-50
72. Li K, Giudice GJ, Tamai K, et al. Cloning of partial cDNA for mouse 180-kDa bullous pemphigoid antigen (BPAG2), a highly conserved collagenous protein of the cutaneous basement membrane zone. J Invest Dermatol 1992; 99: 258-63
73. Fairley JA, Heintz PW, Neuburg M, et al. Expression pattern of the bullous pemphigoid-180 antigen in normal and neoplastic epithelia. Br J Dermatol 1995; 133: 385-91
74. Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993; 92: 2480-8
75. Hashimoto T, Ebihara T, Ishiko A, et al. Comparative study of bullous pemphigoid antigens among Japanese, British, and US patients indicates similar antigen profiles with the 170-kD antigen present both in the basement membrane and on the keratinocytes cell membrane. J Invest Dermatol 1993; 100: 385-9
76. Haase C, Budinger L, Borradori L, et al. Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol 1998; 110: 282-6
77. Korman NJ. In situ-bound antibodies eluted from the skin of patients with bullous pemphigoid are preferentially directed against the 230-kD bullous pemphigoid antigen. J Invest Dermatol 1995; 105: 324-830
78. Ghohestani R, Kanitakis J, Nicolas JF, et al. Comparative sensitivity of indirect immunofluorescence to immunoblot assay for the detection of circulating antibodies to bullous pemphigoid antigens 1 and 2. Br J Dermatol 1996; 135: 74-9
79. Tanaka M, Hashimoto T, Dykes PJ, et al. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles. Clin Exp Dermatol 1996; 21: 23-7
80. Jiao D, Bystryn JC. Relation between antibodies to BP180 and gender in bullous pemphigoid. J Am Acad Dermatol 1999; 41: 269-70
81. Bernard P, Bedane C, Bonnetblanc JM. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol 1997; 136: 694-8
82. Liu Z, Diaz LA, Swartz SJ. Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J Immunol 1995; 155: 5449-54
83. Perriard J, Jaunin F, Favre B, et al. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and intracellular domains of the BP antigen 180. J Invest Dermatol 1999; 112: 141-7
84. Giudice GJ, Emery DG, Zelickson BD, et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993; 151: 5742-50
85. Matsumura K, Amagai M, Nishikawa T, et al. The majority of bullous pemphigoid and herpes gestationis serum samples react with the N16a domain of the 180-kDa bullous pemphigoid antigen. Arch Dermatol Res 1996; 288: 507-9
86. Zillikens D, Rose PA, Balding SD, et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997; 109: 573-9
87. Schmidt E, Obe K, Brocker DB, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136: 174-8
88. Sitaru C, Schmidt E, Petermann S, et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 2002; 118: 664-71
89. Zillikens D, Giudice GJ. BP180/type XVII collagen: its role in acquired and inherited disorders or the dermal-epidermal junction. Arch Dermatol Res 1999; 291: 187-94
90. Bird P, Friedmann PS, Ling N, et al. Subclass distribution of IgG autoantibodies in bullous pemphigoid. J Invest Dermatol 1986; 86: 21-5
91. 4 subclasses. Br J Dermatol 2001; 144: 760-8
92. Wintroub BU, Mihm MC, Goetzl EJ, et al. Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N Engl J Med 1978; 298: 417-21
93. Dvorak AM, Mihm MC, Osage JE, et al. Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast granule changes in multiple biopsies from one patient. J Invest Dermatol 1982; 78: 91-101
94. Chan LS, Vanderlugt CJ, Hashimoto T, et al. Epitope spreading: Lessons from autoimmune skin diseases. J Invest Dermatol 1998; 110: 103-9
95. Skaria M, Jaunin F, Hunziker T, et al. IgG autoantibodies from bullous pemphigoid patients recognise multiple antigenic reactive sites located predominantly within the B and C subdomain of the COOH-terminus of BP230. J Invest Dermatol 2000; 114: 1-7
96. Stanley JR, Tanaka T, Mueller S, et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 1988; 82: 1864-70
97. Rico MJ, Korman NJ, Stanley JR, et al. IgG antibodies from patients with bullous pemphigoid bind to localized epitopes on synthetic peptides encoded by bullous pemphigoid antigen cDNA. J Immunol 1990; 145: 3728-33
98. Tanaka M, Hashimoto T, Amagai M, et al. Characterization of bullous pemphigoid antibodies by use of recombinant bullous pemphigoid antigen proteins. J Invest Dermatol 1991; 97: 725-8
99. Gaucherand M, Nicolas JF, Paranhos Baccala G, et al. Major antigenic epitopes of bullous pemphigoid 230 kDa antigen map within the C-terminal end of the protein: evidence using a 55 kDa recombinant protein. Br J Dermatol 1995; 132: 190-6
100. Ghohestani RF, Cozzani E, Delaporte E, et al. IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230). J Clin Immunol 1998; 18 (3): 202-9
101. Dopp E, Schmidt E, Chimanovitch I, et al. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000; 42: 577-83
102. Bernard P, Aucouturier P, Denis F, et al. Immunoblot analysis of IgG subclasses of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopathol 1990; 54: 484-94
103. Parodi A, Rebora A. Serum IgE antibodies bind to the epidermal side of the basement membrane zone splits in bullous pemphigoid. Br J Dermatol 1992; 126: 526-7
104. Soh H, Hosokawa H, Asada Y. IgE and its related phenomena in bullous pemphigoid. Br J Dermatol 1993; 128: 371-7
105. Schmidt E, Brocker E, Zillikens D. High levels of soluble CD23 in blister fluid of patients with bullous pemphigoid. Arch Dermatol 1995; 131: 966-7
106. Delaporte E, Dubost-Brama A, Ghohestani R, et al. IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid. J Immunol 1996; 157: 3642-7
107. Labib RS, Anhalt GJ, Patel HP, et al. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 1986; 136 (4): 1231-5
108. Kirtschig G, Wojnarowska F. IgA basement membrane zone autoantibodies in bullous pemphigoid detect epidermal antigens of 270-280 kDa, 230 kDa, and 180 kDa molecular weight by immunoblotting. Clin Exp Dermatol 1999; 24: 302-7
109. Schacke H, Schumann H, Hammami-Hauasli N, et al. Two forms of collagen XVII in keratinocytes. J Biol Chem 1998; 273 (40): 25937-43
110. Schaller J, Giese T, Ladusch M, et al. Interleukin-2 receptor expression and interleukin-2 production in bullous pemphigoid. Arch Dermatol Res 1990; 282: 223-6
111. Dubucquoi S, Desreumaux P, Janin A, et al. Interleukin-5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med 1994; 179: 703-8
112. Ameglio F, D'Auria L, Bonifati C, et al. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br J Dermatol 1998; 138: 611-4
113. Schmidt E, Bastian B, Dummer R, et al. Detection of elevated levels of IL-r, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 1996; 288: 353-7
114. Xu L, Robinson N, Miller SD, et al. Characterization of BALB/c mice B lymphocyte autoimmune responses to skin basement membrane component type XVII collagen, the target antigen of autoimmune skin disease bullous pemphigoid. Immunol Lett 2001; 77: 105-11
115. Jordon RE, Kawana S, Fritz KA. Immunopathologic mechanisms in pemphigus and pemphigoid. J Invest Dermatol 1985; 85 (1 Suppl.): 72S-8S
116. Liu Z, Giudice GJ, Swartz SJ, et al. The role of complement in experimental bullous pemihigoid. J Clin Invest 1995; 95: 1539-44
117. Liu Z, Giudice GJ, Zhou X, et al. A major role for neutrophils in experimental Bullous pemphigoid. J Clin Invest 1995; 100: 1256-63
118. Chen R, Ning G, Zhao M, et al. Mast cells play a key role in neutrophils recruitment in experimental bullous pemphigoid. J Clin Invest 2001; 108 (8): 1151-8
119. Gammon WR, Merritt CC, Lewis DM, et al. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes and complement. J Invest Dermatol 1982; 78: 285-90
120. Liu Z, Shipley JM, Vu TH, et al. Gelatinase B-deficient mice are resistant to experimental Bullous pemphigoid. J Exp Med 1998; 188 (3): 475-82
121. Stahle-Backdahl M, Inoue M, Giudice G, et al. 92-kD gelatinase is produced by eosinophils it the site of blister formation in Bullous pemphigoid and cleaves the extracellular domain of recombinant 180-dD bullous pemphigoid autoantigen. J Clin Invest 1994; 93: 2022-30
122. Verraes S, Hornebeck W, Polette M, et al. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 2001; 117: 1091-6
123. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 265-376
124. Yancey KB. From bedside to bench and back: the diagnosis and biology of bullous diseases. Arch Dermatol 1994; 130: 983-7
125. Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet 1999; 354: 667-72
126. Ghohestani RF, Novotney J, Chaudhary M, et al. Bullous pemphigoid: From the bedside to the research laboratory. Clin Dermatol 2001; 19: 690-6
127. Goldberg DJ, Sabolinski M, Bystryn JC. Regional variation in the expression of bullous pemphigoid antigen and location of lesions in bullous pemphigoil. J Invest Dermatol 1984; 82: 326-8
128. Asbrink E, Hovmark A. Clinical variations in bullous pemphigoid with respect to early symptoms. Acta Dermatovener (Stockholm) 1981; 61: 417-21
129. Amato DA, Silverstein J, Ziteili J. The prodrome of bullous pemphigoid. Int J Dermatol 1988; 27: 560-3
130. Wolf R, Ophir J, Dechner E. Nonbullous bullous pemphigoid. Int J Dermatol 1992; 31: 498-500
131. Strohal R, Rappersberger K, Pehamberger H, et al. Nonbullous pemphigoid: prodrome of bullous pemphigoid or a distinct pemphigoid variant? J Am Acad Dermatol 1993; 29: 293-9
132. Alonso-Llamazares J, Rogers PS, Oursler JR, et al. Bullous pemphigoid presenting as generalized pruritus: observations in six patients. Int J Dermatol 1998; 37: 508-14
133. Liu HN, Su WPD, Rogers RS. Clinical variants of pemphigoid. Int J Dermatol 1986; 25: 17-27
134. Powell AM, Albert S, Gratian MJ, et al. Pemphigoid nodularis (non-bullous): a clinicopathological study of five cases. Br J Dermatol 2002; 147: 343-9
135. Person JR, Rogers RS, Perry HO. Localized pemphigoid. Br J Dermatol 1976; 95: 531-4
136. Provost TT, Maize JC, Ahmed AR, et al. Unusual subepidermal bullous diseases with immunologic features of bullous pemphigoid. Arch Dermatol 1979; 115: 156-60
137. Borradori L, Prost C, Wolkenstein P, et al. Localized pretibial pemphigoid and pemphigoid nodularis. J Am Acad Dermatol 1992; 27: 863-7
138. Ernst TM, Marsch WCH. Development of localized pemphigoid following radiation treatment. Dermatolgica 1982; 164: 73-81
139. Parslew R, Verbov JL. Bullous pemphigoid at sites of trauma. Br J Dermatol 1997; 137: 825-6
140. Ghura HS, Johnston GA, Milligan A. Development of a bullous pemphigoid after split-skin grafting. Br J Plast Surg 2001; 54: 447-9
141. Anderson CK, Mowad CM, Goff ME, et al. Bullous pemphigoid arising in surgical wounds. Br J Dermatol 2001; 145: 670-2
142. Yesudian PD, Dobson CM, Ahmad R, et al. Trauma-induced bullous pemphigoid around venous access site in a hemodialysis patient. Clin Exp Dermatol 2002; 27: 70-2
143. Levine N, Freilich A, Barland P. Localized pemphigoid simulating dyshidrosiform dermatitis. Arch Dermatol 1979; 115: 320-1
144. Massa MC, Connolly SM. Bullous pemphigoid with features of prurigo nodularis. Arch Dermatol 1982; 118: 937-9
145. Borradori L, Rybojad M, Verola O, et al. Pemphigoid nodularis. Arch Dermatol 1990; 126: 1522-3
146. Ross JS, McKee PH, Smith NP, et al. Unusual variants of pemphigoid: from pruritus to pemphigoid nodularis. J Cutan Pathol 1992; 19: 212-6
147. Gallo R, Parodi A, Rebora A. Pemphigoid nodularis. Br J Dermatol 1993; 129: 744-5
148. Bourke JF, Berth-Jones J, Gawkrodger DJ, et al. Pemphigoid nodularis: a report of two cases. Clin Exp Dermatol 1994; 19: 496-9
149. Schmidt E, Sitaru C, Schubert B, et al. Subacute prurigo variant of bullous pemphigoid: autoantibodies show the same specificity compared with classic bullous pemphigoid. J Am Acad Dermatol 2002; 47: 133-6
150. Schachter M, Brieva JC, Jones JCR, et al. Pemphigoid nodularis associated with autoantibodies to the NC16A domain of BP180 and a hyperproliferative integrin profile. J Am Acad Dermatol 2001; 45: 747-54
151. Tani M, Murata Y, Masaki H. Pemphigoid nodularis. J Am Acad Dermatol 1989; 21: 1099-104
152. Cliff S, Holden CA. Pemphigoid nodularis: a report of three cases and review of the literature. Br J Dermatol 1997; 136: 398-401
153. Yung SW, Soltani K, Lorincz AL. Pemphigoid nodularis. J Am Acad Dermatol 1981; 5: 54-60
154. Gengoux P, Lachapelle JM. Pemphigoid presenting as atypical excoriated prurigo: regarding 11 cases. Dermatol 1997; 194: 392-4
155. Winkelmann RK, Su WPD. Pemphigoid vegetans. Arch Dermatol 1979; 115: 446-8
156. Kuokkanen K, Helin H. Pemphigoid vegetans. Arch Dermatol 1981; 117: 56-7
157. Chan LS, Dorman MA, Agha A, et al. Pemphigoid vegetans represents a bullous pemphigoid variant. J Am Acad Dermatol 1993; 28: 331-5
158. Korman NJ, Woods SG. Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Br J Dermatol 1995; 133: 967-71
159. Amato L, Gallerani I, Mei S, et al. Erythrodermic bullous pemphigoid. Int J Dermatol 2001; 40: 343-8
160. Tappeiner G, Konrad K, Holubar K. Erythrodermic bullous pemphigoid. J Am Acad Dermatol 1982; 6: 489-92
161. Saitoh A, Atsushi O, Ohtake N. Erythrodermic bullous pemphigoid. J Am Acad Dermatol 1993; 28: 124-5
162. Bean SF, Michel B, Furey N, et al. Vesicular pemphigoid. Arch Dermatol 1976; 112: 1402-4
163. Jawitz J, Kumar V, Nigra TP, et al. Vesicular pemphigoid vs dermatitis herpetiformis. J Am Acad Dermatol 1984; 10: 892-6
164. Sander HM, Utz MMP, Peters MS. Bullous pemphigoid and dermatitis herpetiformis: mixed bullous disease or coexistence of two separate entities? J Cutan Pathol 1989; 16: 370-4
165. Honeyman JF, Honeyman AR, De la Parra MA, et al. Polymorphic pemphigoid. Arch Dermatol 1979; 115: 423-7
166. Cordel N, Courville P, Martel P, et al. Extensive erosive bullous pemphigoid: an atypical serious clinical variant. Br J Dermatol 2002; 146: 537-9
167. Lang PG, Maize JC. Coexisting lichen planus and bullous pemphigoid or lichen planus pemphigoides? J Am Acad Dermatol 1983; 9: 133-40
168. Mora RG, Nesbitt LT, Brantley JB. Lichen planus pemphigoides: clinical and immunofluorescent findings in four cases. J Am Acad Dermatol 1983; 8: 331-6
169. Davis AL, Bhogal BS, Whitehead P, et al. Lichen planus pemphigoides: its relationship to bullous pemphigoid. Br J Dermatol 1991; 125: 263-71
170. Zillikens D, Caux F, Mascaro JM, et al. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the c-terminal NC16A domain of BP180. J Invest Dermatol 1999; 113: 117-21
171. Stingl G, Holubar K. Coexistence of lichen planus and bullous pemphigoid: an immunopathological study. Br J Dermatol 1975; 93: 313-20
172. Joly P, Tanasescu S, Wolkenstein P, et al. Lichenoid erythrodermic bullous pemphigoid of the African patient. J Am Acad Dermatol 1998; 39: 691-7
173. Nemeth AJ, Klein AD, Gould EW, et al. Childhood bullous pemphigoid. Arch Dermatol 1991; 127: 378-86
174. Bean SF, Good RA, Windhorst DB. Bullous pemphigoid in an 11 year old boy. Arch Dermatol 1970; 102: 205-8
175. Fincher DF, Dupree E, Bean SF. Bullous pemphigoid in childhood. Arch Dermatol 1971; 103: 88-90
176. Ostlere LS, Stevens H, Black MM, et al. Bullous pemphigoid in infancy: a case report including new immunoblotting observations. Clin Exp Dermatol 1993; 18: 483-5
177. Ratnavel RC, Shanks AJ, Grant JW. Juvenile pemphigoid nodularis. Br J Dermatol 1994; 130: 125-35
178. Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol 1991; 30: 307-12
179. Fellner MJ. Drug-induced bullous pemphigoid. Clin Dermatol 1993; 11: 515-20
180. Czechowicz RT, Reid CM, Warren LJ, et al. Bullous pemphigoid induced by cephalexin. Australas J Dermatol 2001; 42: 152-5
181. Bart B, Bean S. Bullous pemphigoid following the topical use of fluorouracil. Arch Dermatol 1970; 102: 457-60
182. Thomsen K, Schmidt H. PUVA-induced bullous pemphigoid. Br J Dermatol 1976; 95: 568-9
183. Duschet P, Schwarz S, Gschnait F. Bullous pemphigoid after radiation therapy. J Am Acad Dermatol 1988; 18: 441-4
184. Fournier B, Descamps V, Bouscarat F, et al. Bullous pemphigoid induced by vaccination. Br J Dermatol 1996; 135: 144-61
185. Lear JT, Tan BB, English JSC. Bullous pemphigoid following influenza vaccination [letter]. Clin Exp Dermatol 1996; 21 (5): 392
186. Millard TP, Smith HR, Black MM, et al. Bullous pemphigoid developing during systemic therapy with chloroquine. Clin Exp Dermatol 1999; 24: 263-5
187. Alcalay J, David M, Ingber A, et al. Bullous pemphigoid mimicking bullous erythema multiforme: an untoward side effect of penicillins. J Am Acad Dermatol 1988; 18: 345-9
188. Kodak E, Ben-Shetrit A, Ingber A, et al. Bullous pemphigoid: an adverse effect of ampicillin. Clin Exp Dermatol 1990; 15: 50-2
189. Delbado C, Rieckhoff-Cantoni L, Helg C, et al. Bullous pemphigoid associated with acute graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 10: 377-9
190. Miralles J, Barnadas MA, Baselga E, et al. Bullous pemphigoid-like lesions induced by amoxicillin. Int J Dermatol 1997; 36: 42-7
191. Velthuis PJ, Hendrikse JC, Nefkens JJ. Combined features of pemphigus and pemphigoid induced by penicillamine. Br J Dermatol 1985; 112: 615-9
192. Rasmussen HB, Jepsen LV, Brandrup F. Penicillamine-induced bullous pemphigoid with pemphigus-like antibodies. J Cutan Pathol 1989; 16: 154-7
193. Fellner MJ, Katz JM. Occurrence of bullous pemphigoid after furosemide therapy. Arch Dermatol 1976; 112: 75-7
194. Koch CA, Mazzaferri EL, Larry JA, et al. Bullous pemphigoid after treatment with furosemide. Cutis 1996; 58: 340-4
195. Kashihara M, Danno K, Miyachi Y, et al. Bullous pemphigoid-like lesions induced by phenacetin. Arch Dermatol 1984; 120; 1196-9
196. Pazderka Smith E, Taylor TB, Meyer LJ, et al. Antigen identification in drug-induced bullous pemphigoid. J Am Acad Dermatol 1993; 29: 879-82
197. Laing VB, Sherertz EF, Flowers FP. Pemphigoid-like bullous eruption related to ibuprofen. J Am Acad Dermatol 1988; 19: 91-4
198. Downs AMR, Lear JT, Bower CPR, et al. Does influenza vaccination induce bullous pemphigoid? A report of four cases [letter]. Br J Dermatol 1998; 138 (2): 363
199. Rault S, Grosieux-Dauger C, Verrae S, et al. Bullous pemphigoid induced by fluoxetine. Br J Dermatol 1999; 141: 755-6
200. Grange F, Scrivener Y, Koessler A, et al. Spironolactone-induced pemphigoid. Ann Dermatol Venereol 1997; 124: 700-2
201. Boulinguez S, Bernard P, Bedane C, et al. Bullous pemphigoid induced by bumetanide. Br J Dermatol 1998; 138: 548-9
202. Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid. Arch Dermatol 1996; 132: 272-6
203. Morrison LH, Labib RS, Zone JJ, et al. Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen. J Clin Invest 1988; 81: 2023-6
204. Gee BC, Allen J, Khumalo NP, et al. Bullous pemphigoid in pregnancy: contrasting behaviour in two patients. Br J Dermatol 2001; 145: 994-7
205. Bedane C, McMillan JR, Balding SD, et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitppes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 1997; 108: 901-7
206. Gammon WR, Kowalewski C, Chorzelski TP, et al. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol 1990; 22: 664-70
207. Gammon WR, Briggaman RA, Wheeler CE. Epidermolysis bullosa acquisita presenting as an inflammatory bullous disease. J Am Acad Dermatol 1982; 7: 382-7
208. Gammon WR, Briggaman BA, Woodley DT, et al. Epidermolysis bullosa acquisita: a pemphigoid-like disease. J Am Acad Dermatol 1984; 11: 820-32
209. Tindall JG, Rea TH, Shulman I, et al. Herpes gestationis in association with a hydatid form mole. Arch Dermatol 1981; 117: 510-2
210. Shornick JK, Bangert JL, Freeman RJ, et al. Herpes gestationis: clinical and histologic features of twenty-eight cases. J Am Acad Dermatol 1983; 8: 24-24
211. Lin M, Arteaga LA, Diaz LA. Herpes gestationis. Clin Dermatol 2001; 19: 697-702
212. Jenkins RE, Vaughan Jones SA, Black MM. Conversion of pemphigoid gestationis to bullous pemphigoid: two refractory cases highlighting this association. Br J Dermatol 1995; 135: 595-8
213. Vaillant L, Bernard P, Joly F, et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. Arch Dermatol 1998; 134: 1075-80
214. Bernard P, Venot J, Constant F, et al. Blood eosinophilia as a severity marker for bullous pemphigoid. J Am Acad Dermatol 1987; 16: 879-81
215. Bushkell LL, Jordon RE. Bullous pemphigoid: a cause of peripheral blood eosinophilia. J Am Acad Dermatol 1983; 8: 648-51
216. Arbesman CE, Wypych JI, Reisman RE, et al. IgE levels in sera of patients with pemphigus or bullous pemphigoid. Arch Dermatol 1974; 110: 378-81
217. Heilborn JD, Stahle-Backdahl M, Albertioni F, et al. Low-dose oral pulse methotrexate monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40: 741-9
218. Schaumburg-Lever G, Orfanos CE, Lever WF. Electron microscopic study of bullous pemphigoid. Arch Dermatol 1972; 106: 662-7
219. Nishioka K, Hashimoto K, Katayama I, et al. Eosinophilic spongiosis in bullous pemohigoid. Arch Dermatol 1984; 120: 1166-8
220. Kirtschig G, Wojnarowska F. Autoimmune blistering diseases: an up-date of diagnostic methods and investigations. Clin Exp Dermatol 1994; 19: 97-112
221. Weigand DA. Effect of anatomic region on immunofluorescence diagnosis of bullous pemphigoid. J Am Acad Dermatol 1985; 12: 274-8
222. Gammon WR, Fine J, Forbes M, et al. Immunofluorescence or split skin for the detection and differentiation of basement membrane zone autoantibodies. J Am Acad Dermatol 1992; 27: 79-87
223. Kelly SE, Wojnarowska F. The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemohigoid and cicatricial pemphigoid. Br J Dermatol 1988; 118: 31-40
224. Hachisuka H, Kurose K, Katashima T, et al. Serum from normal elderly individuals contains antibasement membrane zone antibodies. Arch Dermatol 1996; 132: 1201-5
225. Logan RA, Bhogal B, Das AK, et al. Localization of bullous pemphigoid antibody: an indirect immunofluorescence study of 228 cases using a split-skin technique. Br J Dermatol 1987; 117: 471-8
226. Ghohestani RF, Nicolas JF, Rousselle P, et al. Diagnostic value of indirect immunofluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. Arch Dermatol 1997; 133: 1102-7
227. Batteux F, Franck N, Jaffray P, et al. An extract from cultured human keratinocytes that contains the major autoantigens related to autoimmune bullous skin diseases. J Clin Immunol 1997; 17 (3): 228-33
228. Bernard P, Didierjean L, Denis F, et al. Heterogeneous bullous pemphigoid antibodies: detection and characterization by immunoblotting when absent by indirect immunofluorescence. J Invest Dermatol 1989; 92: 171-4
229. Machado P, Michalaki H, Roche P, et al. Serological diagnosis of bullous pemphigoid (BP): comparison of the sensitivity of indirect immunofluorescence on salt-split skin to immunoblotting. Br J Dermatol 1992; 126: 236-41
230. Rieckhoff-Cantoni L, Bernard P, Didierjean L, et al. Frequency of bullous pemphigoid-like antibodies as detected by Western immunoblot analysis in pruritic dermatoses. Arch Dermatol 1992; 128: 791-4
231. Zillikens D, Mascaro JM, Rose PA, et al. A highly sensitive enzyme-linked immunosorbant assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997; 109: 679-83
232. Wojnarowska F, Kirtschig G, Khumalo N. Treatment of subepidermal immunobullous diseases. Clin Dermatol 2001; 19: 768-77
233. Wojnarowska F, Kirtschig G, Highet AS, et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147: 214-21
234. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 825-35
235. Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol 1989; 20: 458-61
236. Paquet PH, Richelle M, Lapiere CM. Bullous pemphigoid treated by topical corticosteroids. Acta Derm Venereol (Stockh) 1991; 71: 534-5
237. Muramatsu T, Lida T, Shira T. Pemphigoid and pemphigus foliaceus successfully treated with topical corticosteroids. J Dermatol 1996; 23: 683-8
238. Claudy A. Evaluation of the safety and efficacy of a potent topical cortico-steroid in the treatment of bullous pemphigoid. Clin Dermatol 2001; 19: 778-80
239. Bystryn JC, Wainwright BD, Shupack JL. Oral and topical steroids in bullous pemphigoid. N Engl J Med 2002; 347 (2): 143-5
240. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346 (5): 321-7
241. Ardern-Jones MR, Yenning VA, Wojnarowska F. Oral and topical corticosteroids in bullous pemphigoid. N Engl J Med 2002; 347 (2): 143-5
242. Stern RS. Bullous pemphigoid therapy: think globally, act locally. N Engl J Med 2002; 346 (5): 364-7
243. Korman NJ. Oral and topical corticosteroids in bullous pemphigoid. N Engl J Med 2002; 347 (2): 143-5
244. Spigel GT. Oral and topical corticosteroids in bullous pemphigoid [letter]. N Engl J Med 2002; 347 (2): 143-5
245. Dreno B, Sassolas B, Lacour P, et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol 1993; 120: 518-21
246. Khumalo NP, Murrell DF, Wojnarowska F, et al. A systemic review of treatments for bullous pemphigoid. Arch Dermatol 2002; 138: 385-9
247. Lebrun-Vignes JC, Roujeau R, Bernard P, et al. Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid. Arch Dermatol 1999; 135: 89-90
248. Siegel J, Eaglstein WH. High-dose methylprednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1984; 120: 1157-65
249. Mutasim DF. Treatment considerations while awaiting the ideal bullous pemphigoid trial. Arch Dermatol 2002; 138 (3): 404
250. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day: a multicenter randomized study. Ann Dermatol Venereol 1984; 111: 925-8
251. Fine JD. Management of acquired bullous skin diseases. N Engl J Med 1995; 333 (22): 1475-84
252. Thornfeldt CR, Menkes AW. Bullous pemphigoid controlled by tetracycline. J Am Acad Dermatol 1987; 16: 305-10
253. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. Arch Dermatol 1986; 122: 670-4
254. Kolbach DN, Remme JJ, Bos WH, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol 1995; 133: 88-90
255. Fox BJ, Odom RB, Findlay RF. Erythromycin therapy in bullous pemphigoid: possible anti-inflammatory effects. J Am Acad Dermatol 1982; 7: 504-10
256. Loo WJ, Kirtschig G, Wojnarowska F. Minocycline as a therapeutic option in bullous pemphigoid. Clin Exp Dermatol 2001; 26: 376-9
257. Thomas I, Khorenian S, Arbesfeld DM. Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol 1993; 28: 74-7
258. Hornschuh B, Hamm H, Wever S, et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol 1997; 36: 101-3
259. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753-8
260. Chaidemenos GC. Tetracycline and niacinamide in the treatment of blistering skin diseases. Clin Dermatol 2001; 19: 781-5
261. Bekier E, Wyczolkowska J, Szych H, et al. The inhibitory effect of nicotinamide on asthma-like symptoms and eosinophilia in guinea pigs, anaphylactic mast cell degranulation in mice, and histamine release from rat peritoneal mast cells by compound 48/80. Int Arch Allergy Appl Immunol 1974; 47: 737-48
262. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978; 70: 51-5
263. Humbert P, Treffel P, Chapius JF, et al. The tetracyclines in dermatology. J Am Acad Dermatol 1991; 25: 691-7
264. Sanchez Miralles E, Nunez Cabezon M, Ledo Pozueta A. Treatment of generalized bullous pemphigoid with oral tetracycline [letter]. J Am Acad Dermatol 1994; 30 (2 Pt 1): 291
265. Burton JL, Harman RRM, Peachey RDG, et al. Azathioprine plus prednisone in treatment of pemphigoid. BMJ 1978; 2: 1190-1
266. Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid: a 4 year follow-up. Br J Dermatol 1974; 91: 103-9
267. Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49-53
268. Anstey A. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 1203-4
269. Paul MA, Jorizzo JL, Fleischer AB, et al. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1994; 31: 620-5
270. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol 1991; 25: 306-18
271. Bohm M, Beissert S, Schwarz T, et al. Bullous pemphigoid treated with mycophenolate mofetil [letter]. Lancet 1997; 349: 541
272. Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 1998; 39: 497-8
273. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999; 40: 957-60
274. Person JR, Rogers RS. Bullous pemphigoid responding to sulphapyridine and the sulphones. Arch Dermatol 1977; 113: 610-5
275. Piamphongsant T. Dapsone for the treatment of bullous pemphigoid. Asian Pac J Allergy Immunol 1983; 1: 19-21
276. Yenning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 1989; 120: 83-92
277. Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear cytotoxicity by dapsone. J Clin Invest 1978; 62: 214-20
278. Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990; 22: 796-801
279. Itoh T, Hosokawa H, Shirai Y, et al. Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide. Br J Dermatol 1996; 134: 931-3
280. Dawe RS, Naidoo DK, Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol 1997; 137: 826-7
281. Thivolet J, Barthelemy H, Rigot-Muller G, et al. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985; I: 334-5
282. Barthelemy H, Thivolet J, Cambazard F, et al. Cyclosporin in the treatment of bullous pimphigoid: preliminary study. Ann Dermatol Vernereol 1986; 113: 309-13
283. Cunliffe WJ. Bullous pempliigoid and response to cyclosporin. Br J Dermatol 1987; 32: 113-4
284. Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide. Arch Dermatol 2000; 136: 1204-5
285. Guillot B, Donadio D, Guilhou JJ, et al. Plasma exchanges in the treatment of bullous pemphigoid. Presse Med 1983; 12 (30): 1855-8
286. Egan CA, Meadows KP, Zone JJ. Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Int J Dermatol 2000; 39: 230-5
287. Wollina U, Lange D, Looks A. Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases. Dermatology 1999; 198: 140-4
288. Roujeau JC, Morel P, Dalle IE, et al. Plasma exchange in bullous pemphigoid. Lancet 1984; II: 486-8
289. Guillot B, Donadio D, Guilhou JJ, et al. Long term plasma exchange therapy in bullous pemphigoid. Acta Derm Venereol (Stockh) 1985; 66: 73-5
290. Beckers RCY, Brand A, Veimeer BJ, et al. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995; 133: 289-93
291. Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 1989; 20: 684-5
292. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865-74
293. Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data. J Am Acad Dermatol 2000; 44: 83-8
294. Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001; 44: 1010-24